Galmed Pharmaceutica (GLMD) 3.85 $GLMD Galmed P
Post# of 273258
Posted On: 09/02/2016 7:01:09 PM
Galmed Pharmaceutica (GLMD) 3.85 $GLMD
Galmed Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
PR Newswire - Wed Aug 03, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today reported financial results for the three and six months ended June 30, 2016. The Company will host a conference call and webcast today to discuss the financial results and to provide an update on current developments with respect to its clinical programs for Aramchol(TM).
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Announces the Appointment of Professor Ran Oren, M.D., as Chief Medical Officer
PR Newswire - Mon Aug 01, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has appointed Professor Ran Oren, M.D., as Chief Medical Officer ("CMO" , effective as of August 1, 2016. Dr. Oren replaces Dr. Maya Halpern, who previously served as Galmed's CMO.
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the Commercialization of Aramchol(TM) in Korea
PR Newswire - Thu Jul 28, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, and SAMIL Pharm. Co., Ltd. ("Samil" today announced the execution of a license agreement (the "Agreement" for an exclusive, royalty-bearing license for the commercialization of Aramchol(TM) (with an option to manufacture) for the treatment of fatty liver indications including nonalcoholic steatohepatitis, or NASH, in the Republic of Korea, along (the "License" .
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China
PR Newswire - Tue Jun 07, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has expanded the clinical operations of its ongoing Phase IIb ARREST study into China and has also commenced a pharmacokinetic ("PK" study in healthy Chinese subjects domiciled in the United States.
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial
PR Newswire - Wed Jun 01, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced that it had randomized half of the patients (N=120) in the ARREST Study.
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
PR Newswire - Mon May 16, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today reported financial results for the three months ended March 31, 2016. The Company will host a conference call and webcast today to discuss the financial results and to provide an update on current developments with respect to its clinical programs for Aramchol(TM).
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals First Quarter 2016 Conference Call and Webcast Scheduled for Monday, May 16th, 2016
PR Newswire - Mon May 09, 7:30AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it will host a conference call and webcast on Monday, May 16th, 2016 to discuss results for the period ended March 31, 2016 and to provide an update on current developments with respect to its clinical programs for Aramchol(TM).
GLMD: 3.85 (+0.05)
Mount Sinai and Galmed Pharmaceuticals to Collaborate in an Investigator Initiated Phase IIa Trial to Evaluate the Effect of AramcholTM in Combination with Vitamin D for the Treatment of Patients with Fibrotic Nonalcoholic Fatty Liver Disease
PR Newswire - Tue May 03, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has signed an investigator initiated clinical trial agreement with the Icahn School of Medicine at Mount Sinai, entitled "A Placebo-controlled Single-blinded Study of AramcholTM with Supplemental Vitamin D in Patients with Vitamin D Deficiency and Nonalcoholic Fatty Liver Disease (NAFLD) and Fibrosis" (the "Study" . The Study, which is a Phase IIa trial, will be conducted under the leadership of principal investigator, Andrea Branch, PhD, Professor of Medicine in the Icahn School of Medicine at Mount Sinai, United States, and an additional center in Israel. Galmed has filed a patent application for the composition of matter patent on the new combination therapy.
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals to Hold a Symposium on Non-Invasive Diagnostics during the International Liver Congress in Spain
PR Newswire - Thu Apr 07, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it will hold the 2nd "NASH 2020" forum entitled "NASH: Beyond Liver Biopsy - Current and Next Generation Diagnostic Methods" during the International Liver Congress (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), on April 16th in Barcelona, Spain.
GLMD: 3.85 (+0.05)
Aramchol(TM) Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease
PR Newswire - Wed Mar 30, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today pre-clinical data demonstrating significant anti-fibrotic activity of AramcholTM in methionine and choline deficient (MCD) diet in mice.
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals (GLMD) Jumps: Stock Rises 7.9%
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 7:15AM CDT
Galmed Pharmaceuticals Ltd. (GLMD) shares rose almost 8% in the last trading session.
GLMD: 3.85 (+0.05), CORT: 5.31 (-0.04)
Galmed Pharmaceuticals (GLMD) Jumps: Stock Up 21.8%
Zacks Equity Research - Zacks Investment Research - Thu Jan 21, 7:15AM CST
Galmed Pharmaceuticals Ltd. (GLMD) shares rose almost 22% in the last trading session.
EARS: 1.71 (unch), GLMD: 3.85 (+0.05)
BUYINS.NET: GLMD SqueezeTrigger Price is $8.49. There is $730,128 That Short Sellers Still Need To Cover.
M2 - Fri Dec 18, 12:18PM CST
BUYINS.NET / www.squeezetrigger.com is monitoring GOLD MEDAL RES LTD (NASDAQ:GLMD) in real time and just received an alert that GLMD is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 84800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $8.49. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
GLMD: 3.85 (+0.05)
Global Non-Alcoholic SteatoHepatitis (NASH) Analysis 2015 - Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunities
M2 - Fri Dec 11, 9:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/m95wfc/nonalcoholic) has announced the addition of the "Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunity in Various Geographies" report to their offering. Sales of Hepatitis C drugs crossed -$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in treatment guidelines along with defined clinical trials endpoint are the concerns for the emerging therapy. US FDA is expected to release guidelines for the clinical trial in CY16 and this should accelerate the development of the drugs targeting NASH. NASH is the progressive form of Non-Alcoholic Fatty Liver Disease - NAFLD. While NASH can reverse itself, in many cases, the resulting liver scarring causes a patient's liver to harden and failure to work properly. It is estimated that NASH affects 2 to 5% of the US population. Other developed countries such as Europe and Japan also have similar or higher incidence of NASH disease. Due to the varying physical and metabolism traits across various geographies, development of drugs for NASH is facing difficulty. In Japan, the prevalence of NASH is rising although the population is not typically overweight. Countries like India and China with bigger population and changes in lifestyles face a greater risk of NASH along with other lifestyle diseases like Diabetes and Cardiovascular related complexities. As per the US Association of Liver Disease, of those who develop NASH, -15-25% will progress to end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) over 10-20 years. Today, 1/3rd of Liver transplants and HCC are caused by NASH and the total cost burden of this on US is over -$5 billion per year. Only new treatments in NASH could lead to a cut in this major cost burden along with improving quality of life. Since a new innovation in NASH has been enlightened, the interest in companies developing drugs for NASH has also gone up. In Jan. 2015, Gilead Sciences (GILD) acquired Phenex Pharma's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH) and other Liver Diseases. Merck-NGM Biopharma and Boehringer Ingelheim - Pharmaxis also entered into an exclusive agreement for the pipeline products which are being developed for NASH with a potential deal value of -$450-600mn. This report will provide detailed analysis on NASH disease and Drugs in development in broader pharma market. This report list all the drugs in clinical trial and their design and the population recruited, also tells about the pathways representing possible targets for the treatment of NASH. Key Topics Covered: 1. Executive Summary 2. Overview of NASH 2.1 Possible targets for the treatment of NASH 2.2 Drugs in the pipeline 2.3 Key Milestones 2.4 Drivers of M&A/ Licensing deals in NASH 2.5 NASH disease market opportunity to 2025 3. Products in Development and Competitive Landscape 3.1 Key Drugs/Companies Developing Drugs Against NASH 3.1.1 Obeticholic Acid - Intercept Pharmaceuticals/ Dainippon Sumitomo 3.1.2 Elafibranor - Genfit 3.1.3 Multiple programs - Gilead 3.1.4 Emricasan - Conatus Pharmaceuticals 3.1.5 Aramchol - Galmed Pharmaceuticals 3.1.6 Cenicriviroc - Tobira Therapeutics 3.1.7 IMM-124E - Immuron 3.1.8 GR-MD-02 - Galectin Therapeutics 3.1.9 TD139 - Galecto Biotech 3.1.10 SHP626 - Shire 3.1.11 PXS4728A - Boehringer Ingelheim 3.2 Repurposed Drugs for NASH 3.2.1 Remogliflozin etabonate - Islet Sciences/BHV pharma 3.2.2 Lipaglyn (saroglitazar) - Cadila Healthcare 3.2.3 Victoza (liraglutide) - Novo Nordisk 4. NASH - Etiology, Pathogenesis, Diagnosis and Current Treatment 4.1 Cause, Symptoms, Pathogenesis, Diagnosis 4.2 Current treatment including Herbal Medicine 5. Regulatory Pathway 5.1 Challenges in trials using endpoints to define clinically meaningful benefits 5.2 Potential Clinical Trial Design for NASH and Endpoints 6. Annexure Companies Mentioned - Boehringer Ingelheim - Cadila Healthcare - Conatus Pharmaceuticals - Galectin Therapeutics - Galecto Biotech - Galmed Pharmaceuticals - Genfit - Gilead - Immuron, - Intercept Pharmaceuticals/ Dainippon Sumitomo - Islet Sciences/BHV pharma - Novo Nordisk - Shire - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/m9...nalcoholic
NVO: 45.80 (-0.54), GLMD: 3.85 (+0.05), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), CNAT: 1.84 (-0.02), GALT: 1.70 (+0.05), ICPT: 150.74 (+3.92), TBRA: 5.14 (+0.06)
StockNewsNow.com Publishes New SNNLive Video Interview With Galmed Pharmaceuticals Ltd.
Marketwired - Wed Dec 02, 7:01AM CST
StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Josh Blacher, CFO of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, according to the Company's website (see here: www.GalmedPharma.com). The video interview was recorded on Thursday, October 15th, 2015 at the Dawson James Small Cap Growth Conference 2015 in Jupiter, FL.
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol(TM) for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease
PR Newswire - Tue Dec 01, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared Galmed's Investigational New Drug (IND) application for the ARRIVE Study (ARamcholTM for the Reversal of HIV-AssociatEd Lipodystrophy and NAFLD), a proof-of-concept clinical trial that will evaluate the safety and efficacy of AramacholTM in up to 50 patients with HIV-associated lipodystrophy and nonalcoholic fatty liver disease, or NAFLD.
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals reports 3Q loss
Automated Insights - Mon Nov 09, 7:17AM CST
TEL AVIV, Israel (AP) _ Galmed Pharmaceuticals Ltd. (GLMD) on Monday reported a loss of $2.6 million in its third quarter.
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Announces Commencement of Patient Screening for the ARREST Study in Europe, and Reports Third Quarter 2015 Financial Results
PR Newswire - Mon Nov 09, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced the commencement of patient screening for the ARREST Study in Europe, and reported financial results for the three and nine months ended September 30, 2015.
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Third Quarter 2015 Conference Call and Webcast Scheduled for November 9, 2015
PR Newswire - Mon Nov 02, 7:30AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, announced today that it will host a conference call and webcast on Monday, November 9, 2015 to discuss results for the period ended September 30, 2015 and to provide an update on current developments with respect to its clinical program for Aramchol(TM).
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
PR Newswire - Wed Aug 03, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today reported financial results for the three and six months ended June 30, 2016. The Company will host a conference call and webcast today to discuss the financial results and to provide an update on current developments with respect to its clinical programs for Aramchol(TM). GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Announces the Appointment of Professor Ran Oren, M.D., as Chief Medical Officer
PR Newswire - Mon Aug 01, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has appointed Professor Ran Oren, M.D., as Chief Medical Officer ("CMO" , effective as of August 1, 2016. Dr. Oren replaces Dr. Maya Halpern, who previously served as Galmed's CMO. GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the Commercialization of Aramchol(TM) in Korea
PR Newswire - Thu Jul 28, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, and SAMIL Pharm. Co., Ltd. ("Samil" today announced the execution of a license agreement (the "Agreement" for an exclusive, royalty-bearing license for the commercialization of Aramchol(TM) (with an option to manufacture) for the treatment of fatty liver indications including nonalcoholic steatohepatitis, or NASH, in the Republic of Korea, along (the "License" . GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China
PR Newswire - Tue Jun 07, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has expanded the clinical operations of its ongoing Phase IIb ARREST study into China and has also commenced a pharmacokinetic ("PK" study in healthy Chinese subjects domiciled in the United States. GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial
PR Newswire - Wed Jun 01, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced that it had randomized half of the patients (N=120) in the ARREST Study. GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
PR Newswire - Mon May 16, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today reported financial results for the three months ended March 31, 2016. The Company will host a conference call and webcast today to discuss the financial results and to provide an update on current developments with respect to its clinical programs for Aramchol(TM). GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals First Quarter 2016 Conference Call and Webcast Scheduled for Monday, May 16th, 2016
PR Newswire - Mon May 09, 7:30AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it will host a conference call and webcast on Monday, May 16th, 2016 to discuss results for the period ended March 31, 2016 and to provide an update on current developments with respect to its clinical programs for Aramchol(TM). GLMD: 3.85 (+0.05)
Mount Sinai and Galmed Pharmaceuticals to Collaborate in an Investigator Initiated Phase IIa Trial to Evaluate the Effect of AramcholTM in Combination with Vitamin D for the Treatment of Patients with Fibrotic Nonalcoholic Fatty Liver Disease
PR Newswire - Tue May 03, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has signed an investigator initiated clinical trial agreement with the Icahn School of Medicine at Mount Sinai, entitled "A Placebo-controlled Single-blinded Study of AramcholTM with Supplemental Vitamin D in Patients with Vitamin D Deficiency and Nonalcoholic Fatty Liver Disease (NAFLD) and Fibrosis" (the "Study" . The Study, which is a Phase IIa trial, will be conducted under the leadership of principal investigator, Andrea Branch, PhD, Professor of Medicine in the Icahn School of Medicine at Mount Sinai, United States, and an additional center in Israel. Galmed has filed a patent application for the composition of matter patent on the new combination therapy. GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals to Hold a Symposium on Non-Invasive Diagnostics during the International Liver Congress in Spain
PR Newswire - Thu Apr 07, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it will hold the 2nd "NASH 2020" forum entitled "NASH: Beyond Liver Biopsy - Current and Next Generation Diagnostic Methods" during the International Liver Congress (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), on April 16th in Barcelona, Spain. GLMD: 3.85 (+0.05)
Aramchol(TM) Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease
PR Newswire - Wed Mar 30, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today pre-clinical data demonstrating significant anti-fibrotic activity of AramcholTM in methionine and choline deficient (MCD) diet in mice. GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals (GLMD) Jumps: Stock Rises 7.9%
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 7:15AM CDT
Galmed Pharmaceuticals Ltd. (GLMD) shares rose almost 8% in the last trading session.
GLMD: 3.85 (+0.05), CORT: 5.31 (-0.04)
Galmed Pharmaceuticals (GLMD) Jumps: Stock Up 21.8%
Zacks Equity Research - Zacks Investment Research - Thu Jan 21, 7:15AM CST
Galmed Pharmaceuticals Ltd. (GLMD) shares rose almost 22% in the last trading session.
EARS: 1.71 (unch), GLMD: 3.85 (+0.05)
BUYINS.NET: GLMD SqueezeTrigger Price is $8.49. There is $730,128 That Short Sellers Still Need To Cover.
M2 - Fri Dec 18, 12:18PM CST
BUYINS.NET / www.squeezetrigger.com is monitoring GOLD MEDAL RES LTD (NASDAQ:GLMD) in real time and just received an alert that GLMD is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 84800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $8.49. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
GLMD: 3.85 (+0.05)
Global Non-Alcoholic SteatoHepatitis (NASH) Analysis 2015 - Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunities
M2 - Fri Dec 11, 9:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/m95wfc/nonalcoholic) has announced the addition of the "Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunity in Various Geographies" report to their offering. Sales of Hepatitis C drugs crossed -$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in treatment guidelines along with defined clinical trials endpoint are the concerns for the emerging therapy. US FDA is expected to release guidelines for the clinical trial in CY16 and this should accelerate the development of the drugs targeting NASH. NASH is the progressive form of Non-Alcoholic Fatty Liver Disease - NAFLD. While NASH can reverse itself, in many cases, the resulting liver scarring causes a patient's liver to harden and failure to work properly. It is estimated that NASH affects 2 to 5% of the US population. Other developed countries such as Europe and Japan also have similar or higher incidence of NASH disease. Due to the varying physical and metabolism traits across various geographies, development of drugs for NASH is facing difficulty. In Japan, the prevalence of NASH is rising although the population is not typically overweight. Countries like India and China with bigger population and changes in lifestyles face a greater risk of NASH along with other lifestyle diseases like Diabetes and Cardiovascular related complexities. As per the US Association of Liver Disease, of those who develop NASH, -15-25% will progress to end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) over 10-20 years. Today, 1/3rd of Liver transplants and HCC are caused by NASH and the total cost burden of this on US is over -$5 billion per year. Only new treatments in NASH could lead to a cut in this major cost burden along with improving quality of life. Since a new innovation in NASH has been enlightened, the interest in companies developing drugs for NASH has also gone up. In Jan. 2015, Gilead Sciences (GILD) acquired Phenex Pharma's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH) and other Liver Diseases. Merck-NGM Biopharma and Boehringer Ingelheim - Pharmaxis also entered into an exclusive agreement for the pipeline products which are being developed for NASH with a potential deal value of -$450-600mn. This report will provide detailed analysis on NASH disease and Drugs in development in broader pharma market. This report list all the drugs in clinical trial and their design and the population recruited, also tells about the pathways representing possible targets for the treatment of NASH. Key Topics Covered: 1. Executive Summary 2. Overview of NASH 2.1 Possible targets for the treatment of NASH 2.2 Drugs in the pipeline 2.3 Key Milestones 2.4 Drivers of M&A/ Licensing deals in NASH 2.5 NASH disease market opportunity to 2025 3. Products in Development and Competitive Landscape 3.1 Key Drugs/Companies Developing Drugs Against NASH 3.1.1 Obeticholic Acid - Intercept Pharmaceuticals/ Dainippon Sumitomo 3.1.2 Elafibranor - Genfit 3.1.3 Multiple programs - Gilead 3.1.4 Emricasan - Conatus Pharmaceuticals 3.1.5 Aramchol - Galmed Pharmaceuticals 3.1.6 Cenicriviroc - Tobira Therapeutics 3.1.7 IMM-124E - Immuron 3.1.8 GR-MD-02 - Galectin Therapeutics 3.1.9 TD139 - Galecto Biotech 3.1.10 SHP626 - Shire 3.1.11 PXS4728A - Boehringer Ingelheim 3.2 Repurposed Drugs for NASH 3.2.1 Remogliflozin etabonate - Islet Sciences/BHV pharma 3.2.2 Lipaglyn (saroglitazar) - Cadila Healthcare 3.2.3 Victoza (liraglutide) - Novo Nordisk 4. NASH - Etiology, Pathogenesis, Diagnosis and Current Treatment 4.1 Cause, Symptoms, Pathogenesis, Diagnosis 4.2 Current treatment including Herbal Medicine 5. Regulatory Pathway 5.1 Challenges in trials using endpoints to define clinically meaningful benefits 5.2 Potential Clinical Trial Design for NASH and Endpoints 6. Annexure Companies Mentioned - Boehringer Ingelheim - Cadila Healthcare - Conatus Pharmaceuticals - Galectin Therapeutics - Galecto Biotech - Galmed Pharmaceuticals - Genfit - Gilead - Immuron, - Intercept Pharmaceuticals/ Dainippon Sumitomo - Islet Sciences/BHV pharma - Novo Nordisk - Shire - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/m9...nalcoholic
NVO: 45.80 (-0.54), GLMD: 3.85 (+0.05), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), CNAT: 1.84 (-0.02), GALT: 1.70 (+0.05), ICPT: 150.74 (+3.92), TBRA: 5.14 (+0.06)
StockNewsNow.com Publishes New SNNLive Video Interview With Galmed Pharmaceuticals Ltd.
Marketwired - Wed Dec 02, 7:01AM CST
StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Josh Blacher, CFO of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, according to the Company's website (see here: www.GalmedPharma.com). The video interview was recorded on Thursday, October 15th, 2015 at the Dawson James Small Cap Growth Conference 2015 in Jupiter, FL.
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol(TM) for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease
PR Newswire - Tue Dec 01, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared Galmed's Investigational New Drug (IND) application for the ARRIVE Study (ARamcholTM for the Reversal of HIV-AssociatEd Lipodystrophy and NAFLD), a proof-of-concept clinical trial that will evaluate the safety and efficacy of AramacholTM in up to 50 patients with HIV-associated lipodystrophy and nonalcoholic fatty liver disease, or NAFLD. GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals reports 3Q loss
Automated Insights - Mon Nov 09, 7:17AM CST
TEL AVIV, Israel (AP) _ Galmed Pharmaceuticals Ltd. (GLMD) on Monday reported a loss of $2.6 million in its third quarter.
GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Announces Commencement of Patient Screening for the ARREST Study in Europe, and Reports Third Quarter 2015 Financial Results
PR Newswire - Mon Nov 09, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"
, a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced the commencement of patient screening for the ARREST Study in Europe, and reported financial results for the three and nine months ended September 30, 2015. GLMD: 3.85 (+0.05)
Galmed Pharmaceuticals Third Quarter 2015 Conference Call and Webcast Scheduled for November 9, 2015
PR Newswire - Mon Nov 02, 7:30AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, announced today that it will host a conference call and webcast on Monday, November 9, 2015 to discuss results for the period ended September 30, 2015 and to provide an update on current developments with respect to its clinical program for Aramchol(TM). GLMD: 3.85 (+0.05)
(0)
(0)Scroll down for more posts ▼